Metal-organic frameworks: A novel platform for combined advanced therapies

Rojas, Sara; Arenas‐Vivo, Ana; Horcajada, Patricia

doi:10.1016/j.ccr.2019.02.032

Cited by 224 publications

(146 citation statements)

References 154 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Owing to the heterogeneity and complexity of tumors, monotherapy has many restrictions that make eradicating tumor tissue difficult. Combined therapy, however, can effectively overcome the shortcomings of monotherapy and further improve the therapeutic effect. The versatility of COFs allows different therapies to be easily combined on COF‐nanoplatforms.…”

Section: Combined Therapymentioning

confidence: 99%

Covalent Organic Frameworks (COFs) for Cancer Therapeutics

Guan

Zhou

et al. 2020

Chemistry A European J

154

View full text Add to dashboard Cite

As newly emerged crystalline porous materials, covalent organic frameworks (COFs) possess fascinating structures and some specific features such as modularity,c rystallinity,p orosity,s tability, versatility,a nd biocompatibility.B esides adsorption/separation, sensing, catalysis, and energy applications, COFs have recently shown ap romise in biomedical applications. This contribution provides an overview of the recent developments of COF-based medicines in cancer therapeutics, including drug delivery,p hotodynamic therapy( PDT), photothermal therapy (PTT), and combined therapy. Furthermore, the major challengesa nd developing trends in this field are also discussed. These recent developments are summarized and discussed to help encourage further contributions in this emerging and promisingf ield.[a] Q.

show abstract

Section: Combined Therapymentioning

confidence: 99%

Covalent Organic Frameworks (COFs) for Cancer Therapeutics

Guan

Zhou

et al. 2020

Chemistry A European J

154

View full text Add to dashboard Cite

show abstract

“…For example, captopril and amlodipine can be co‐encapsulated with thiazide‐type diuretics for antihypertensive treatments, which not only reduces the risk of side‐effects but also softens blood vessel effectively . In addition, combined drug therapies have also reported to reduce drug resistance …”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

“…[174] In addition, combined drug therapies have also reported to reduce drug resistance. [175] In ADRS, drug release can be triggered by more than one endogenous stimulation signal to incorporate more functionalities and enhance the versatility of treatments. For example, proteins such as cytochrome C and caspase-3 need to be transported to specific intracellular compartments such as cytoplasm.…”

Section: Opportunities and Perspectivesmentioning

confidence: 99%

Autonomous Drug Release Systems with Disease Symptom‐Associated Triggers

Xiong

Niu

et al. 2020

Advanced Intelligent Systems

View full text Add to dashboard Cite

Many biophysical and biochemical properties of pathogenic tissues are different from those of healthy tissues. These disease symptom‐associated properties include pH, reduction–oxidation conditions, enzyme generation and expression, blood glucose concentration, mechanical stiffness and strain, and temperature. Autonomous drug release that uses one or more of these disease symptom‐associated properties as the release trigger minimizes the delay in treatments and allows for the release of medications with precisely controlled amounts and with desired spatiotemporal patterns. Herein, a comprehensive assessment of current research progress on autonomous drug release systems (ADRS) is provided. The representative symptoms‐associated properties that can be potentially used as the endogenous stimuli are introduced. The autonomous drug systems that utilize these symptom‐associated signals as the endogenous stimulation signals are discussed, followed by the discussion of current challenges and opportunities in this field, as well as possible future directions in ADRS.

show abstract

“…Many clinical anticancer treatments involve a cocktail of drugs (e.g. FOLFORINOX combines 5‐FU , leucovorin, irinotecan and oxaliplatin against metastatic pancreatic adenocarcinoma) yet examples of MOFs capable of delivering multiple drugs are relatively scarce, suggesting defect‐loading could be an attractive strategy for preparing multimodal chemotherapeutic formulations.…”

Section: Introductionmentioning

confidence: 99%

Multivariate Modulation of the Zr MOF UiO‐66 for Defect‐Controlled Combination Anticancer Drug Delivery

2020

View full text Add to dashboard Cite

Metal–organic frameworks (MOFs) are emerging as leading candidates for nanoscale drug delivery, as a consequence of their high drug capacities, ease of functionality, and the ability to carefully engineer key physical properties. Despite many anticancer treatment regimens consisting of a cocktail of different drugs, examples of delivery of multiple drugs from one MOF are rare, potentially hampered by difficulties in postsynthetic loading of more than one cargo molecule. Herein, we report a new strategy, multivariate modulation, which allows incorporation of up to three drugs in the Zr MOF UiO‐66 by defect‐loading. The drugs are added to one‐pot solvothermal synthesis and are distributed throughout the MOF at defect sites by coordination to the metal clusters. This tight binding comes with retention of crystallinity and porosity, allowing a fourth drug to be postsynthetically loaded into the MOFs to yield nanoparticles loaded with cocktails of drugs that show enhancements in selective anticancer cytotoxicity against MCF‐7 breast cancer cells in vitro. We believe that multivariate modulation is a significant advance in the application of MOFs in biomedicine, and anticipate the protocol will also be adopted in other areas of MOF chemistry, to easily produce defective MOFs with arrays of highly functionalised pores for potential application in gas separations and catalysis.

show abstract

Metal-organic frameworks: A novel platform for combined advanced therapies

Cited by 224 publications

References 154 publications

Covalent Organic Frameworks (COFs) for Cancer Therapeutics

Covalent Organic Frameworks (COFs) for Cancer Therapeutics

Autonomous Drug Release Systems with Disease Symptom‐Associated Triggers

Multivariate Modulation of the Zr MOF UiO‐66 for Defect‐Controlled Combination Anticancer Drug Delivery

Contact Info

Product

Resources

About